Current reports
6-K
Notice of Cancellation of Admission to Trading on Aim
23 Feb 23
6-K
Current report (foreign)
17 Feb 23
6-K
Current report (foreign)
7 Feb 23
6-K
4D pharma Announces an Update on Administration and Suspension of Trading
3 Jan 23
6-K
4D pharma’s Blautix® Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics
18 Nov 22
6-K
Current report (foreign)
15 Nov 22
6-K
Current report (foreign)
7 Oct 22
6-K
Delay to publication of Interim Results
30 Sep 22
6-K
Current report (foreign)
24 Aug 22
6-K
Delisting of Securities of 4D pharma plc from The Nasdaq Stock Market
24 Aug 22
Registration and prospectus
25-NSE
Exchange delisting
19 Jul 22
F-3
Shelf registration (foreign)
21 Apr 22
S-8
Registration of securities for employees
1 Apr 22
F-3/A
Shelf registration (foreign) (amended)
28 Mar 22
F-3
Shelf registration (foreign)
8 Mar 22
424B3
Prospectus supplement
18 Feb 22
424B3
Prospectus supplement
18 Feb 22
424B3
Prospectus supplement
10 Jan 22
424B3
Prospectus supplement
10 Jan 22
424B3
Prospectus supplement
14 Oct 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
29 Apr 22
UPLOAD
Letter from SEC
26 Apr 22
CORRESP
Correspondence with SEC
26 Apr 22
EFFECT
Notice of effectiveness
31 Mar 22
CORRESP
Correspondence with SEC
28 Mar 22
UPLOAD
Letter from SEC
14 Mar 22
EFFECT
Notice of effectiveness
15 Oct 21
CORRESP
Correspondence with SEC
12 Oct 21
EFFECT
Notice of effectiveness
4 Oct 21
UPLOAD
Letter from SEC
21 Sep 21